SCHEMBL31104666

SCHEMBL31104666

CC(C)(C)c1ccc(-c2cc(/C=C3\SC(=O)NC3=O)ncn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.48
▸ ADAMTS5 Q9UNA0 1/20 0.48
▸ PIM1 P11309 9/20 0.47
▸ PIM2 Q9P1W9 8/20 0.44
▸ PTGS1 P23219 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ PARP1 P09874 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CISD1 Q9NZ45 4/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ CLK1 P49759 1/20 0.41
▸ CSNK2B P67870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25282486 1.00 NR1H4 (0.48) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25238361 1.00 NR1H4 (0.48) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25242245 0.82 PIM1 (0.50) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25282477 0.82 PIM1 (0.50) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25248590 0.81 ADAMTS5 (0.56) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25287160 0.81 ADAMTS5 (0.56) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL1250027 0.77 PIM1 (0.71) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL1250028 0.77 PIM1 (0.71) NR1H4ADAMTS5PIM1PIM2PTGS1
SCHEMBL25243513 0.74 ALDH1A1 (0.43) NR1H4HPGDNPC1RAB9APIK3CD
SCHEMBL30479919 0.74 ALDH1A1 (0.43) NR1H4HPGDNPC1RAB9APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 — — US claimed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 — — EP claimed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 — — CN claimed
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 — — US disclosed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 — — EP disclosed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME SREBF1, SREBF2, SP1 NR1H4 128/4885ADAMTS5 2398/4885PIM1 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback